<SEC-DOCUMENT>0001213900-26-044318.txt : 20260416
<SEC-HEADER>0001213900-26-044318.hdr.sgml : 20260416
<ACCEPTANCE-DATETIME>20260416070016
ACCESSION NUMBER:		0001213900-26-044318
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260416
FILED AS OF DATE:		20260416
DATE AS OF CHANGE:		20260416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		26865646

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0286617-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>April 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number:</B>&nbsp; <B>001-38723</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tiziana Life Sciences LTD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>107 Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>EC2V 6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of registrant&rsquo;s principal executive
office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F&nbsp;</FONT><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Form&nbsp;40-F&nbsp;</FONT><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">On April 16, 2026, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;)
issued this 6K announcing, the publication of positive preclinical data in a bioRxiv preprint. The study, titled &ldquo;Intranasal Anti-CD3
Antibody Treatment Attenuates Post COVID Neuroinflammation and Enhances Hippocampal Neurogenesis and Cognitive Function in Mice,&rdquo;
demonstrates that nasal anti-CD3 treatment significantly reduces neuroinflammation, boosts regulatory T cells (Tregs) in the brain, restores
hippocampal neurogenesis, and improves short-term memory in a model of Long COVID.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: April 16, 2026</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ea028661701ex99-1.htm">Tiziana Life Sciences LTD Press Release, dated April 16, 2026</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea028661701ex99-1.htm
<DESCRIPTION>TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED APRIL 16, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="ea028661701_ex99-1img1.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tiziana Life Sciences Announces Publication
of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Data from independent academic collaborators published on bioRxiv support
the therapeutic potential of the Company&rsquo;s lead candidate, intranasal foralumab, for Long COVID associated &ldquo;brain fog&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOSTON, MA, April 16, 2026</B> &ndash; Tiziana Life Sciences, Ltd.
(Nasdaq: TLSA) (&ldquo;Tiziana&rdquo;), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3
monoclonal antibody, announces the publication of positive preclinical data in a bioRxiv preprint. The study, titled &ldquo;Intranasal
Anti-CD3 Antibody Treatment Attenuates Post COVID Neuroinflammation and Enhances Hippocampal Neurogenesis and Cognitive Function in Mice,&rdquo;
demonstrates that nasal anti-CD3 treatment significantly reduces neuroinflammation, boosts regulatory T cells (Tregs) in the brain, restores
hippocampal neurogenesis, and improves short-term memory in a model of Long COVID.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Conducted by leading researchers including co-corresponding authors
Akiko Iwasaki, Ph.D. (Yale University) and Howard L. Weiner, M.D. (Brigham and Women&rsquo;s Hospital, Harvard Medical School), the study
used a respiratory restricted mild SARS-CoV-2 mouse model that recapitulates key neurological features of Long COVID without direct brain
infection. Nasal administration of anti-CD3 monoclonal antibody either shortly after infection or in the chronic phase increased brain
FoxP3+ IL-10+ Tregs, reprogrammed microglia from a pro-inflammatory to a regulatory phenotype, reduced gliosis (astrocytes and microglia)
in white matter and hippocampus, normalized CCL11 levels, restored neurogenesis, and rescued cognitive deficits. Human observational data
in the study further showed that Long COVID patients with neurological symptoms exhibit lower circulating Treg levels, reinforcing the
translational relevance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The full preprint is available on bioRxiv and has not yet been peer-reviewed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Link here: https://www.biorxiv.org/content/10.64898/2026.04.07.716934v1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These findings show that nasal anti-CD3 can potently induce regulatory
T cells that cross into the brain and dampen persistent neuroinflammation triggered by even mild respiratory viral infection. By reprogramming
microglia, reducing harmful chemokines like CCL11, and restoring the hippocampal neurogenic niche, this approach offers a promising, non-invasive
strategy to address the cognitive impairment often called &lsquo;brain fog&rsquo; that continues to affect millions of Long COVID patients
worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Howard L. Weiner, co-corresponding author, Director of the Ann
Romney Center for Neurologic Diseases at Brigham and Women&rsquo;s Hospital, and Chair of the Scientific Advisory Board of Tiziana Life
Sciences, added: &ldquo;This study builds on our extensive work with nasal anti-CD3 and highlights its ability to modulate the immune
system at the mucosal surface to promote central nervous system repair. The broad therapeutic window, effective both early and late after
infection, and the lack of impact on antiviral immunity make intranasal foralumab an exciting candidate for clinical development in post-viral
neuroinflammatory conditions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented:
&ldquo;We are thrilled to see these robust preclinical data in BioRxiv, further validating the broad therapeutic potential of our intranasal
foralumab platform. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, and these results directly
support the mechanistic foundation for our ongoing programs in non active secondary progressive multiple sclerosis, MSA, Alzheimer&rsquo;s
disease, and ALS.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tiziana&rsquo;s intranasal foralumab has previously demonstrated favorable
safety and signals of clinical benefit in an expanded access program in non-active secondary progressive multiple sclerosis, with reductions
in microglial activation observed via PET imaging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Foralumab</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic
candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary
Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328)
with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently
being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active
secondary progressive multiple sclerosis (NCT06292923).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb)
currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory
and neurodegenerative human diseases.<SUP>[1],[2],[3]</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">[1]</TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2220272120</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">[2]</TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2309221120</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">[3]</TD><TD STYLE="text-align: justify">https://www.neurology.org/doi/10.1212/NXI.0000000000200543</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Tiziana Life Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tiziana is a clinical-stage biopharmaceutical company developing breakthrough
therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana&rsquo;s innovative
nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV)
delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development,
has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana&rsquo;s technology for alternative
routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about Tiziana and its innovative pipeline of therapies,
please visit www.tizianalifesciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements made in this announcement are forward-looking statements.
These forward-looking statements are not historical facts but rather are based on the Tiziana&rsquo;s current expectations, estimates,
and projections about its industry, its beliefs, and assumptions. Words such as &lsquo;anticipates,&rsquo; &lsquo;expects,&rsquo; &lsquo;intends,&rsquo;
&lsquo;plans,&rsquo; &lsquo;believes,&rsquo; &lsquo;seeks,&rsquo; &lsquo;estimates,&rsquo; and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties,
and other factors, some of which are beyond the Tiziana&rsquo;s control, are difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the forward-looking statements. Tiziana cautions security holders and prospective security
holders not to place undue reliance on these forward-looking statements, which reflect the view of Tiziana only as of the date of this
announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important
factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled &lsquo;Risk
Factors&rsquo; in Tiziana&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2024, and other periodic reports filed with
the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date
on which the statements are made. Tiziana will not undertake any obligation to release publicly any revisions or updates to these forward-looking
statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required
by law or by any appropriate regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tiziana Life Sciences Ltd</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Spencer, Business Development, and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028661701_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028661701_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V .P# 2(  A$! Q$!_\0
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MP[=:]J$.CR0?#:SG0/X@\0*UT%M_$=Q$NDZ=+F6PBO[E(IH/Z3_AYH.H^%O
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M.GZ1_P '67BOP!<?\%"?C'K'BC0?VA?B1X[;P]=^&_'4?_"974'A_6?B1?\
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MN=,@U.QOKCP_=O<:1<NNJV[V$]S!):7<JO:&6&X>W28 _FI^!_\ RNB>.?\
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M_@[QYH=O%)>:=J>J75I;WFFZK;Q2V,,#O:O(7E?]._\ B-P_8^_Z,U_:+_\
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M8 JRL"&5E/!5AD,I&",@C&:X;P7\+OAG\-QJX^'7P[\"^ 1K]TM]KP\%>$M
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M"?C35+3X<>'O OPTUOP;(?C!\/?%GP_@TG6-3\=>'/%&H>(M2N[G4+J632A
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M?AS\.O G@"VNCFY@\$^$?#_A2&X8D',\6A:?8)*VX YD5CD ]:T?&7@3P/\
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M?B#I6J:=-??"SX:65OJ.I0:'%X"T74'M=<GT.22"&74XIK=;E&N&GDC<N44
M?LC_ ,%'_P!N*;]@3X,Z)\:+OX6VOQ7\)W/BD>'?&6A?\)@WA/6K/2+S2KV6
M*^\/B7PIXFTS7+O[;##!<Z3JLNAVLEE+/*NIB5$@D_FW^"7_  2]^,7_  4O
M'Q3_ &YOV>OC/H?_  3Y^$7[0WQ6U3Q7X2_9W^"U]XGNM*M8])\(^"_"&J>.
JO&?]E:7X+\/V_P 1O'.L^'=0UCQ-:^&](ET:*(Z;Y6I7UTUY("B@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
